Calidi Biotherapeutics, Inc.
CLDI
$1.36
$0.010.74%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.34% | -17.87% | -18.57% | -35.91% | -36.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.65% | -3.59% | -7.05% | -28.18% | -32.43% |
| Operating Income | 10.65% | 3.59% | 7.05% | 28.18% | 32.43% |
| Income Before Tax | 12.68% | 4.69% | 9.67% | 23.40% | 13.75% |
| Income Tax Expenses | 88.89% | 23.08% | 7.14% | 150.00% | -55.00% |
| Earnings from Continuing Operations | 12.63% | 4.67% | 9.66% | 23.35% | 13.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -81.38% | -42.96% | 137.88% | 1,266.67% | -- |
| Net Income | 11.98% | 4.40% | 10.10% | 24.08% | 14.60% |
| EBIT | 10.65% | 3.59% | 7.05% | 28.18% | 32.43% |
| EBITDA | 12.53% | 3.10% | 8.26% | 33.89% | 37.88% |
| EPS Basic | 77.66% | 82.67% | 86.63% | 87.45% | 89.17% |
| Normalized Basic EPS | 85.23% | 84.60% | 87.97% | 88.47% | 76.80% |
| EPS Diluted | 77.66% | 82.67% | 86.63% | 87.45% | 89.17% |
| Normalized Diluted EPS | 85.23% | 84.60% | 87.97% | 88.47% | 76.80% |
| Average Basic Shares Outstanding | 536.94% | 444.80% | 543.61% | 569.25% | 580.28% |
| Average Diluted Shares Outstanding | 536.94% | 444.80% | 543.61% | 569.25% | 481.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |